Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37843
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCUPPENS, Kristof-
dc.contributor.authorBaas, Paul-
dc.contributor.authorGEERDENS, Ellen-
dc.contributor.authorCruys, Bert-
dc.contributor.authorFROYEN, Guy-
dc.contributor.authorDecoster, Lynn-
dc.contributor.authorTHOMEER, Michiel-
dc.contributor.authorMAES, Brigitte-
dc.date.accessioned2022-08-03T08:14:02Z-
dc.date.available2022-08-03T08:14:02Z-
dc.date.issued2022-
dc.date.submitted2022-06-13T14:42:36Z-
dc.identifier.citationLung cancer, 170-
dc.identifier.issn0169-5002-
dc.identifier.urihttp://hdl.handle.net/1942/37843-
dc.description.abstractImmune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing.-
dc.description.sponsorshipAcknowledgments The authors would like to thank Kristine Jinnett and Kirsten Curnow (Illumina, Inc.) for their manuscript preparation assistance. Funding This work was partially supported by the provision of sequencing reagents and sequencing analysis tools by Illumina, Inc-
dc.language.isoen-
dc.publisher-
dc.rights2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).-
dc.subject.otherHED-
dc.subject.otherHLA-I diversity-
dc.subject.otherHLA-I evolutionary divergence-
dc.subject.otherNon-small cell lung cancer-
dc.subject.otherPD-1 immunotherapy-
dc.subject.otherTSO500-
dc.subject.otherTumor mutational burden-
dc.titleHLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors-
dc.typeJournal Contribution-
dc.identifier.epage10-
dc.identifier.spage1-
dc.identifier.volume170-
local.format.pages10-
local.bibliographicCitation.jcatA1-
local.publisher.placeELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.lungcan.2022.05.019-
dc.identifier.pmid35689896-
dc.identifier.isi000861749300001-
dc.identifier.eissn1872-8332-
local.provider.typePubMed-
local.dataset.doi10.1016/j.lungcan.2022.05.019-
local.uhasselt.internationalyes-
item.contributorCUPPENS, Kristof-
item.contributorBaas, Paul-
item.contributorGEERDENS, Ellen-
item.contributorCruys, Bert-
item.contributorFROYEN, Guy-
item.contributorDecoster, Lynn-
item.contributorTHOMEER, Michiel-
item.contributorMAES, Brigitte-
item.fullcitationCUPPENS, Kristof; Baas, Paul; GEERDENS, Ellen; Cruys, Bert; FROYEN, Guy; Decoster, Lynn; THOMEER, Michiel & MAES, Brigitte (2022) HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. In: Lung cancer, 170.-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
item.validationecoom 2023-
crisitem.journal.issn0169-5002-
crisitem.journal.eissn1872-8332-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1-s2.0-S0169500222004640-main.pdfPublished version3.68 MBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

12
checked on Apr 30, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.